As of May 5, 2021, Korea allows a four-year re-examination period for pediatric drugs upon regulatory approval based on foreign clinical trials. The re-examination period acts as de facto data exclusivity, impacting drug protection strategies for originator and generic companies.
July 2021, Managing IP